Ad hoc: . Quarter /: Ad hoc: Carl Zei Meditec achieved sales grow in the first six mons of the financial year 0/0 of around %

JENA/Germany, 02.04.2013.

In the first six months of the financial year 2012/2013, Carl Zeiss Meditec has achieved a turnover of approx. 442 million (previous year:

431.8 million), which corresponds to a growth compared to the previous year of around 3%. Adjusted for currency effects, revenues increased by approximately 4%.

Sales in the Microsurgery strategic business unit grew in the first six months of the current financial year by about 6% compared to last year and reached approximately 207 million (previous year: 195.1 million).

In the Ophthalmic Systems strategic business unit revenues of approximately 176 million (previous year: 184.8 million) were achieved, which corresponds to a decline of around 5%. Although order intake in this business unit developed well compared to last year, revenue generation in the second quarter was somewhat slower than expected, meaning that it remains uncertain whether the target of at least equaling market growth can be achieved by the end of the current financial year.

The Surgical Ophthalmology strategic business unit continued its positive development. Sales in the first 6 months grew by around 16% compared to the previous year and amounted to approxi-

mately 60 million (previous year: 51.9 million).

Jann Gerrit Ohlendorf

Director Corporate Communications

Carl Zeiss Meditec AG

Phone: +49 3641 220-331

Fax: +49 3641 220-332

E-Mail:

press.meditec@zeiss.com

Henriette Meyer

Director Investor Relations

Carl Zeiss Meditec AG

Tel.: +49 3641 220-106

Fax:

E-Mail:

investors.meditec@zeiss.com

Carl Zeiss Meditec AG

Carl Zeiss Meditec AG (ISIN: DE0005313704) is one of the world's leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumables. The company creates innovative visualization solutions in the field of microsurgery. Carl Zeiss Meditecs medical technology portfolio is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In fiscal year 2011/12 (ended 30 September) the companys around 2,400 employees generated revenue of just under EUR 862 million. Carl Zeiss Meditec headquarters are located in Jena, Germany.

The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research in India (CARIn) in Bangalore, India, and the Carl Zeiss Innovation Center for Research and Development in Shanghai, China, strengthen the companys presence in these fast-growing countries. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 65% are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. In the markets for Industrial Solutions, Research Solutions, Medical Technology and Consumer Optics, Carl Zeiss has contributed to technological progress for more than 160 years and enhances the quality of life of many people around the globe. Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Foundation.

For more information please go to: www.meditec.zeiss.com

Number: 0054-2013-ENG OP

Number of Words: 221

Number of Characters: 1372

LINK:	http://applications.zeiss.com/C1256A770030BCE0/WebViewTopNewsAllE/725C...
	See more stories from zeiss

Most recent headlines